Quinolones as Broad-spectrum Agents

  • H. C. Neu
Chapter
Part of the Springer Series in Applied Biology book series (SSAPPL.BIOLOGY)

Abstract

In a few short years, the new quinolone antimicrobial agents have been established as the therapy of many infections. It is reasonable to question whether this class of antimicrobial agent can truly be considered broad-spectrum in the way that the penicillins, cephalosporins, tetracyclines, chloramphenicol, and trimethoprim/sulfamethoxazole are. This report will review the characteristics of the new and future quinolones which show that these agents are broad-spectrum compounds.

Keywords

Antimicrob Agent Minimal Bactericidal Concentration Generation Cephalosporin Acute Lower Respiratory Tract Infection Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bayer AS (1989) Treatment of experimental and human bacterial endocarditis and meningitis with quinolone antimicrobial agents. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents, Washington DC, American Society for Microbiology pp 213–232Google Scholar
  2. Bergan T (1988) Pharmacokinetics of fluorinated quinolones. In: Andriole VT (ed) The Quinolones, London Academic Press, pp 119–154Google Scholar
  3. Brown AE, Smith G (1989) Intravenous ciprofloxacin as treatment of sepsis in selected patients with neoplastic diseases. Am J Med 87: (Suppl 5a) 266F–268FCrossRefGoogle Scholar
  4. Chin NX, Neu HC (1987) Post-antibiotic suppressive effect of ciprofloxacin against Gram-positive and Gram-negative bacteria. Am J Med 82 (4A):58–62PubMedGoogle Scholar
  5. Dallabetta GA, Hookew HI (1989) Treatment of sexually transmitted diseases with quinolone antimicrobial agents. In:Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents, Washington DC, American Society for Microbiology, pp 125–142Google Scholar
  6. Drusano GL (1989) Pharmacokinetics of the quinolone antimicrobial agents. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents, Washington DC, American Society for Microbiology, pp 71–106Google Scholar
  7. Dupont HL (1989) Quinolone antimicrobial agents in the management of bacterial enteric infections. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents, Washington DC, American Society for Microbiology pp 167–176Google Scholar
  8. Eliopoulos GM, Eliopoulos CT (1989) Quinolone antimicrobial agents activity in vitro. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents, Washington DC, American Society for Microbiology, pp 35–90Google Scholar
  9. Flaherty J, Edin B, Waitley D, George D, Sexton B, Anow P, O’Keefe P, Weinstein RA (1989) Multicenter, randomized trial of ciprofloxacin (IV/PO) plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 87: (Suppl 5a) 278F–282FCrossRefGoogle Scholar
  10. Fontaine O (1989) Antibiotics in the management of Shigellosis in children: What role for the quinolones? Rev Infect Dis 11 (5):S145–S150CrossRefGoogle Scholar
  11. Gerding DN, Hitt JA (1989) Tissue penetration of the new quinolones in humans. Rev Infect Dis 11(5):S1046–S1057PubMedCrossRefGoogle Scholar
  12. Hooton TM, Latham RH, Wong ES, Johnson C, Roberts PL, Stamm WE (1989) Ofloxacin versus trimethoprim/sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Chemother 33:1308–1312PubMedGoogle Scholar
  13. Kuschner R, Briones F, Scully BE, Neu HC (1989) Evaluation of IV ofloxacin as therapy of acute lower respiratory tract infections. Abstract #547, 29th Intersci Conv Antimicrob Agents Chemother, Houston, Texas, SeptemberGoogle Scholar
  14. Lee T, Rosenwasser BE, Neu HC (1990) An oral antibiotic regimen for the treatment of chronic osteomyelitis. 57th Am Acad Ortho Surg, Abstract #487, February 13 1990Google Scholar
  15. Naber KG (1989) Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 11(5):1321–1337CrossRefGoogle Scholar
  16. Neu HC (1985) Antimicrobial activity, bacterial resistance, and antimicrobial pharmacology. Am J Med 78(6B):17–22PubMedCrossRefGoogle Scholar
  17. Neu HC (1986) Antimicrobial activity and pharmacokinetics, the importance of integration of these factors to achieve optimal chemotherapy. In: Genazzani E (ed) Pharmacokinetics and Antibiotic Efficacy. Masson, Milano, pp 77–89Google Scholar
  18. Neu HC (1989a) Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis 11(5):S1025–S1035PubMedCrossRefGoogle Scholar
  19. Neu HC (1989b) The quinolones. Infect Dis Clin N Am 3:625–639Google Scholar
  20. Neu HC (1989c) New oral and parenteral quinolones. Am J Med 87: (Suppl 5a) 283F–287FCrossRefGoogle Scholar
  21. Neu HC, Novelli A, Chin NX (1989) Comparative in vitro activity of a new quinolone AM-1091. Antimicrob Agents Chemother 33:1009–1018PubMedGoogle Scholar
  22. Nord CE (1989) Surgical prophylaxis and treatment of surgical infections with quinolones. Rev Infect Dis 11(5): S1287–S1291PubMedCrossRefGoogle Scholar
  23. Oriel JD (1989) Use of quinolones in chlamydial infections. Rev Infect Dis 11(5):S1273–S1276PubMedCrossRefGoogle Scholar
  24. Phillips I, King A, Shannon K (1988) In vitro properties of the quinolones. In: Andriole VT (ed) The Quinolones. Academic Press, pp 83–118Google Scholar
  25. Rolston KVI, Haron E, Cunningham C, Bodey GP (1989) Intravenous ciprofloxacin for infections in cancer patients. Am J Med 87: (Suppl 5a) 261F–265FCrossRefGoogle Scholar
  26. Rosenberg-Arska M, Dekker AVW, Verhoff J (1989) Prevention of infections in granulocytopenic patients by fluorinated quinolones. Rev Infect Dis 11(5):S1231–S1236CrossRefGoogle Scholar
  27. Scully BE (1989) Treatment of respiratory tract infections with quinolone antimicrobial agents. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents. Washington DC, American Society for Microbiology, pp 143–166Google Scholar
  28. Thys JP, Jacobs F, Monte S (1989) Quinolone in the treatment of lower respiratory tract infections. Rev Infect Dis 11 (Suppl):S1212–S1219PubMedCrossRefGoogle Scholar
  29. Winston DJ (1989) Use of quinolone antimicrobial agents in immunocompromised patients. In: Wolfson JS, Hooper DC (eds) Quinolone Antimicrobial Agents. Washington DC, American Society for Microbiology, pp 187–212Google Scholar
  30. Waldvogel FA (1989) Use of quinolones for the treatment of osteomyelitis and septic arthritis. Rev Infect Dis 11(5):S1259–S1263PubMedCrossRefGoogle Scholar
  31. Zeiler HJ, Voigt WH (1987) Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. Am J Med 82(4A):87–90PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1990

Authors and Affiliations

  • H. C. Neu

There are no affiliations available

Personalised recommendations